AM Batteries Opens Doors to Customers, Expediting Electrode Sales for Next Generation Batteries

AM Batteries, a pioneer in dry battery electrode (DBE) technology, opened its state-of-the-art Customer Success Center Monday, enabling the development of next-generation batteries with advanced manufacturing technology. AM Batteries’ new facility will play a crucial role in ongoing efforts to secure the U.S. battery manufacturing supply chain. The ribbon-cutting ceremony was attended by U.S. Representative Lori Trahan (D-MA) and Massachusetts’ Interim Secretary of Economic Development Ashley Stolba.

EnCharge AI Announces EN100, First-of-its-Kind AI Accelerator for On-Device Computing

EnCharge AI today announced the EnCharge EN100, the industry’s first AI accelerator built on precise and scalable analog in-memory computing. Designed to bring advanced AI capabilities to laptops, workstations, and edge devices, EN100 leverages transformational efficiency to deliver 200+ TOPS of total compute power within the power constraints of edge and client platforms such as laptops.

Excision BioTherapeutics Presents Data from HBV and HSV Programs at the ASGCT 2025 Annual Meeting

Excision BioTherapeutics, Inc. (“Excision” or the “Company”), a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced new data presentations from its preclinical programs, hepatitis B virus (HBV), EBT-107 and herpes simplex virus (HSV-1) keratitis, EBT-104 at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 13–17 in New Orleans, Louisiana.

CytoTronics Expands Pixel Capability with Multi-modal Cardiac Application for Early Screening of Drug Candidates in Cardiovascular Research

CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, launched their novel Cardiac application today—the next key offering in its Pixel application portfolio. The first-of-its-kind, multi-modal application lets drug discovery scientists focused on cardiovascular disease and cardiotoxicology measure the electrical activity, contractility and structure of cardiomyocytes in a single assay at scale in 96-and 384-well plates.

1Cell.Ai and BioSkryb Announce Strategic Partnership to Advance Single Cell Multi-omics Innovation

1Cell.Ai, a global leader in single cell precision diagnostics, has joined forces with BioSkryb Genomics, a pioneer in single cell multi-omics, to co-develop and commercialize next-generation single cell multi-omic solutions. This collaboration will empower researchers and clinicians to detect and characterize rare mutations in single cells with unprecedented accuracy, facilitating breakthroughs in cancer research and enabling earlier detection and targeted therapy development.

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

BioSkryb Genomics and Tecan Group (SIX Swiss Exchange: TECN), today introduced a high-throughput single-cell workflow, combining BioSkryb’s 384-well format of the ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit with the Uno Single Cell Dispenser™, provided by Tecan. The integrated solution enables parallel high-resolution analysis of hundreds to thousands of individual cells, addressing growing demand for scalable, multiomics approaches in single-cell research. By reducing reliance on time consuming cell sorting techniques, such as fluorescence-activated cell sorting (FACS), the workflow offers a more streamlined and accessible approach to comprehensive genomic and transcriptomic profiling.

BioSkryb Genomics and Ultima Genomics Launch Collaborative Grant Program to Advance Oncology Research

BioSkryb Genomics, a pioneer in single-cell and ultra–low-input multi-omic solutions, and Ultima Genomics, a leader in scalable and cost-effective sequencing, today announced a collaboration designed to accelerate next-generation oncology research. By combining BioSkryb’s best-in-class single-cell amplification and multi-omic platforms with Ultima’s ultra-high-throughput, cost-efficient sequencing technology, this collaboration aims to provide researchers with comprehensive, high-resolution insights into complex cancer genomics, ultimately driving discoveries that can inform improved patient outcomes.